SLXN
Silexion Therapeutics Corp Ordinary SharesSLXN
SLXN
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
3.19% less ownership
Funds ownership: 11.95% [Q3] → 8.76% (-3.19%) [Q4]
40% less funds holding
Funds holding: 5 [Q3] → 3 (-2) [Q4]
54% less capital invested
Capital invested by funds: $613K [Q3] → $281K (-$332K) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
381%
upside
Avg. target
$5
381%
upside
High target
$5
381%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Naz Rahman 8% 1-year accuracy 1 / 12 met price target | 381%upside $5 | Buy Maintained | 20 Mar 2025 |
Financial journalist opinion
Based on 7 articles about SLXN published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Silexion's new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and previous promising clinical data from its first-generation product; Company shares its strategic roadmap for SIL204's clinical development including plans to initiate human trials in H1 2026 Silexion's new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and previous promising clinical data from its first-generation product; Company shares its strategic roadmap for SIL204's clinical development including plans to initiate human trials in H1 2026

Neutral
GlobeNewsWire
1 week ago
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the Presentation Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the Presentation

Neutral
GlobeNewsWire
2 weeks ago
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse models; Recent funding strengthens the company's ability to deliver long term value Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse models; Recent funding strengthens the company's ability to deliver long term value

Neutral
Business Wire
2 weeks ago
PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment
NEW YORK--(BUSINESS WIRE)---- $SLXN #biotech--PESG Research releases a report covering Silexion Therapeutics' (NASDAQ: SLXN)* latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SIL204 therapeutic candidate. The latest findings represents a critical milestone in the fight against KRAS-driven cancers, particularly pancreatic cancer, showcasing significant potential in addressing one of oncology's most challenging targets. The.

Positive
Benzinga
3 weeks ago
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer
Silexion Therapeutics Corp. SLXN released data on Wednesday from orthotopic pancreatic cancer models demonstrating that subcutaneously administered SIL204 effectively reduces primary tumor growth and metastatic spread.

Neutral
GlobeNewsWire
3 weeks ago
Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic Cancer Cells Grow in Their Native Environment Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic Cancer Cells Grow in Their Native Environment

Neutral
Business Wire
4 weeks ago
PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational
NEW YORK--(BUSINESS WIRE)---- $SLXN #biotech--PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models, a critical milestone that could continue to position its next-generation RNAi therapy at the forefront of KRAS-driven cancer treatment. With data analysis now underway and initial results expected in the coming weeks, according to the company's latest announcement,.

Neutral
GlobeNewsWire
1 month ago
Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks

Neutral
GlobeNewsWire
2 months ago
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company's ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-282932). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.3 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about January 30, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

Neutral
Business Wire
2 months ago
PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market
NEW YORK--(BUSINESS WIRE)---- $SLXN #biotech--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of SIL-204, potentially opening new frontiers in treating KRAS-driven cancers. This development comes amid increasing industry appetite for innovative oncology assets, exemplified by recent multi-billion dollar acquisitions. Silexion's latest precli.

Charts implemented using Lightweight Charts™